Cite
HARVARD Citation
Popat, S. et al. (n.d.). Brigatinib vs crizotinib in ALK TKI-naive ALK+ NSCLC: final results from ALTA-1L. Lung cancer. pp. S27-S28. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Popat, S. et al. (n.d.). Brigatinib vs crizotinib in ALK TKI-naive ALK+ NSCLC: final results from ALTA-1L. Lung cancer. pp. S27-S28. [Online].